Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  etoposide phosphate
Find trials that include:  Any drugs shown
Results 1-25 of 33 for your search:
Start Over
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Status: Active
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, 1407-GUCG, 2014-003930-17, PA031102_A01PAMDREVW01, NCT02375204
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756, NCT02883049
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer [IMpower133]
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO30081, NCI-2016-01683, 2015-004861-97, NCT02763579
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: AMC-097, NCI-2015-01745, 097, 9933, NCT02797470
Lenalidomide, Combination Chemotherapy, and Rituximab in Treating Patients with Primary Effusion Lymphoma or KSHV-Associated Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0171, NCI-2016-01483, P162804, NCT02911142
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00000922, NCI-2013-00781, CR00018679, CR00021317, CR00022743, CR00023930, eIRB #922, MR00041590, ONC-02019-L, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients with Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0264, NCI-2011-02000, CDR0000662814, NCT01042522
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0367, NCI-2014-01356, NCT02106988
Microtransplantation in Treating Younger Patients with Refractory or Relapsed Hematological Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: MITREL, NCI-2015-00691, NCT02433483
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients with Small Cell Lung Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9974, NCI-2016-01363, NCT02899728
Vorinostat, Niacinamide, and Etoposide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NYU 09-0621, NCI-2011-02695, NCT00691210
Belinostat, Cisplatin, and Etoposide in Treating Patients with Recurrent or Advanced Small Cell Lung Cancer or Neuroendocrine Cancer
Status: Temporarily closed
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0173, NCI-2013-01451, 090173, 09-25-0099, NCI 8238, P09511, 8238, NCT00926640
Hypofractionated Proton Beam Radiation Therapy, Cisplatin, and Etoposide Followed by Surgery in Treating Patients with Stage IIIA-B Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-253, NCI-2012-00672, NCT01565772
Brentuximab Vedotin, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-040, NCI-2013-01114, NCT01830777
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: BECHEM, NCI-2013-01148, TEVA ISS, NCT01900509
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients with Stage IIIA-IIIB Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-021, NCI-2013-01835, 1307012220, NCT01958372
Pomalidomide after Combination Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 9524, NCI-2013-02426, J13128, NA_00089739, NCT02029950
Ibrutinib and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9588, NCI-2014-00571, 14-145, NCT02219737
Yttrium Y 90 Basiliximab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Mature T-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 14349, NCI-2015-00019, 116688, NCT02342782
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients with Small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-1003, NCI-2015-00598, NCT02402920
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-221-C-001, NCI-2015-02291, NCT02632708
Start Over